You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.
After comparing manual methods with the firm's pcr.ai tool in more than 20,000 cases, they found that the use of AI improved test accuracy and reliability.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
The Paige Prostate solution and Insight viewer are vendor-neutral and allow pathologists to view whole digitized slides from different sites and scanners.
The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.
The firm said that receipt of the CE mark accelerates its entry into the diagnostic pathology market in Europe and other key geographies globally.
The two companies have been working together since February and now are formalizing plans to develop and test new products.
Philips said an AI prototype that evaluated combinations of vital signs and other biomarkers may predict infection up to 48 hours in advance of clinical suspicion.
Called the "Ccheck Prostate Cancer Confirmation" test, Anixa's assay integrates flow cytometry and machine learning to identify evidence of cancer in a person's bloodstream.
The company said its APAS Independence platform can process 200 culture plates per hour and automatically remove nonsignificant plates from the workflow.